ƒŠƒEƒ}ƒ`‚Ì•W€Ž¡—Ãi‚P‚Qj

ŠÖ߃ŠƒEƒ}ƒ`‚ɑ΂·‚鶕¨Šw“I»ÜŽs”̌㒲¸

2003 ”N‚ÉinfliximabA2005”N‚Éetanercept‚ª“ú–{‚ÅŽg—p‰Â”\‚É‚È‚èŽs”ÌŒã‘S—á’²¸‚ªs‚í‚ꂽB2008”N‚É‚ÍtocilizumabA adalimubmab‚ª“ú–{‚ÅŽg—p‰Â”\‚ƂȂ茻ݎs”ÌŒã‘S—á’²¸’†‚Å‚ ‚éB“Á‚É׋۫”x‰ŠAƒJƒŠƒj”x‰ŠAŒ‹Šj‚É‹C‚ð‚‚¯‚È‚¯‚ê‚΂Ȃç‚È‚¢BƒJƒŠƒj”x‰Š‚Æ Œ‹Šj‚Í“Š–ò—\–h‚ª‰Â”\‚È‚Ì‚Å‚ƒŠƒXƒNŠ³ŽÒ‚Å‚Í—\–h“Š–ò‚ðl—¶‚µ‚½‚Ù‚¤‚ª‚æ‚¢‚ÆŽv‚í‚ê‚éB

“ú–{‚Å‚ÌinfliximabŽs”ÌŒã5000—á‚Ì’²¸‚É‚¨‚¯‚éd“Ä‚È—LŠQŽ–Û‚ÍA308—á 6.2%‚Å‚ ‚Á‚½B

׋۫”x‰Ši108—á 2.2“j’j«A‚—îAis‚µ‚½RAA”xŽ¾Š³‡•¹Š³ŽÒ‚ȂǂŃŠƒXƒN‚ª2”{’ö“x㸂·‚é

ŠÔŽ¿«”x‰Ši25—á 0.‚T“j

ƒJƒŠƒj”x‰Ši22—á 0.4“j65ΈÈãAPSL 6mg/“úˆÈãA”xŽ¾Š³‚̇•¹—á‚ŃŠƒXƒN‚ª2-3”{㸂·‚éB2ˆöŽqˆÈã•Û—L‚È‚çST‡Ü‚É‚æ‚é—\–h‚ðl—¶BŽ€–S—¦27“‚Ì•ñ‚ ‚èB

Œ‹Šji14—á 0.3“jƒc”½‹­—z«‚ȂljߋŽ‚ÌŠ´õŠù‰‚ª‹^‚í‚ê‚éê‡INH‚Ì—\–h“Š—^‚ðl—¶

“ú–{‚Å‚ÌetanerceptŽs”ÌŒã7091—á‚Ì’²¸‚É‚¨‚¯‚éd“Ä‚È—LŠQŽ–Û‚ÍA403—á 5.7“‚Å‚ ‚Á‚½B

ŒÄ‹zŠúŠ´õÇ 367—á 5.56“i׋۫”x‰Š96—á 1.35“, ƒJƒŠƒj”x‰Š 16—á 0.23“, Œ‹Šj 10—á 0.14“j

ŠÔŽ¿«”x‰Š 44—á 0.62“

”畆“î•”‘gDŠ´õÇ 40—á 0.56“

‘SgáŠQA“Š—^‹ÇŠ—l‘Ô 39—á 0.18“

o“T
**Takeuchi T et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 67(2):189-94 2008. **Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 52(6):1481-4 2007. **Fujieda Y et al •ªŽqƒŠƒEƒ}ƒ`Ž¡—à 1(2)14-17 2008. **Enbrel.jp

ƒŠƒEƒ}ƒ`‚Ì•W€Ž¡—Ãi‚Pj i‚Qji‚Rji‚Sji‚Tji‚Uji‚Vji‚Wji‚Xji‚P‚Oji‚P‚Pji‚P‚Qji‚P‚Rji‚P‚Sji‚P‚Tji‚P‚Uji‚P‚Vj
ŠÖ߃ŠƒEƒ}ƒ`‘ŠúŽ¡—ÂÌd—v«
TNF‘jŠQ–ò–³Œø‚ÌŠÖ߃ŠƒEƒ}ƒ`  ‰p‘—§—Õ°•]‰¿Œ¤‹†ŠiNICEj‚ªŽ¡—ÃKƒCƒ_ƒ“ƒX‘ˆÄ‚ð”­•\

ŽŸƒy[ƒW‚ÖFè’JŒ¤‹†Š‚̃ŠƒEƒ}ƒ`Ž¡—Ãí—ª

ƒy[ƒWƒgƒbƒv‚Ö